HPV types 16, 18, and 45 are linked to various cancers, notably cervical cancer, with types 16 and 18 causing about 70% of cases. With over 600,000 new cervical cancer cases annually as of July 2024, early screening is crucial. Traditional methods may be slow, delaying follow-up and treatment.
This kit offers rapid detection of HPV types 16, 18, and 45 DNA in cervical and vulvovaginal swabs, aiding early diagnosis and cancer prevention.

Traditional STI tests often have long processing times and less accuracy, delaying diagnosis. Rapid testing is crucial for managing and preventing infections. With over 130 million new cases of Chlamydia trachomatis and 80 million of Neisseria gonorrhoeae globally each year, quick and precise tests are vital. This kit offers rapid in vitro detection of CT, NG, and Ureaplasma urealyticum DNA in vulvovaginal and male urethral swabs, aiding early diagnosis and screening.

Accurate detection of Group B Streptococcus (GBS) is crucial due to its risks during childbirth, such as severe infections in newborns. GBS affects 10-30% of pregnant women and is linked to 150,000 stillbirths and infant deaths annually. Traditional tests are often cumbersome and slow, delaying diagnosis.
This kit offers rapid in vitro detection of GBS DNA in vaginal swabs from pregnant women at 35-37 weeks, providing timely diagnosis to prevent complications.

Trichomonas Vaginalis (TV) is a common sexually transmitted parasite, and Mycoplasma genitalium (MG) is a bacterium causing urethritis and cervicitis. Early detection is key for preventing reproductive health issues and controlling STI spread. This kit provides in vitro qualitative detection of TV and MG DNA from vaginal, cervical, and male urethral swabs, as well as urine. It offers crucial molecular diagnostic evidence for early STD diagnosis and screening of high-risk populations.